Tesaro surges 60% after GlaxoSmithKline agrees to buy it for $5.1 billion

Investing News

Tesaro shares surged more than 60 percent in premarket trading Monday after GlaxoSmithKline agreed to buy the cancer treatment company for $75 per share, or about $5.1 billion.

The deal represents a more than 60 percent premium over Tesaro’s closing price on Friday of $46.38 per share. GlaxoSmithKline’s stock was more than 5 percent lower in premarket trading Monday.

“The acquisition of Tesaro will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities,” GlaxoSmithKline CEO Emma Walmsley said in a press release.

Bloomberg reported last month that Tesaro was exploring the opportunity of a sale. Tesaro’s shares have suffered losses after it shared disappointing results on Nov. 9 for treatment of small cell lung cancer.

The deal announced Monday was unanimously approved by Tesaro’s board. GlaxoSmithKline expects the deal to close in the first quarter of 2019.

Products You May Like

Articles You May Like

5 Top Stock Trades for Thursday: NVTA, MU, NVDA, AAPL, TWLO
3 Dividend Stocks to Power Through Earnings Season
One tech stock is up 300 percent in a year, but chart analyst calls it a FOMO rally
Mattel has worst day in nearly 20 years after undercutting analysts’ 2019 estimates
Stocks making the biggest moves premarket: Hilton Worldwide, Dish Network, Deere, GM & more

Leave a Reply

Your email address will not be published. Required fields are marked *